Trevi Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Trevi Therapeutics, Inc. (TRVI), a Delaware corporation, filed this Current Report on Form 8-K on September 30, 2021. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to raise gross proceeds of approximately $11.8 million. The transaction structure includes:
- Common Stock: 2,373,201 shares sold at a combined price of $1.62 per share (including accompanying warrants).
- Pre-Funded Warrants: Warrants to purchase up to 4,926,069 shares sold at a combined price of $1.619 per warrant (including accompanying warrants).
- Warrant Terms:
- Common Stock Warrants: Exercise price of $1.37 per share; exercisable immediately. Half expire in 3.5 years, half in 7 years.
- Pre-Funded Warrants: Exercise price of $0.001 per share; exercisable immediately.
- Ownership Caps: Beneficial ownership is limited to 4.99% for Common Stock Warrants and 9.99% for Pre-Funded Warrants, subject to waiver with 61 days' notice.
The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Agreements
On September 30, 2021, the Company executed a Registration Rights Agreement with the Purchaser. Key terms include:
- The Company must file a registration statement for the resale of securities within 15 days of the agreement date.
- Liquidated Damages: If the registration statement is not effective within specified timelines or ceases to be effective, the Company must pay 1.0% of the aggregate amount invested per 30-day period, capped at 10.0% of the investment.
- Placement Agents: Stifel, Nicolaus & Company, Incorporated (lead) and Needham & Company, LLC (co-agent).
Guidance, Risks, and Contingencies
The Private Placement is expected to close on or about October 4, 2021, subject to customary closing conditions. The Company highlighted several risks in its forward-looking statements:
- Uncertainty regarding the satisfaction of closing conditions.
- Risks related to product candidate development, clinical trial success, and timing.
- Impact of the COVID-19 pandemic on clinical operations.
- Uncertainties regarding the Company's cash runway and ability to continue as a going concern.
Investor Verification Checklist
- Verify the actual closing date of the Private Placement (expected October 4, 2021).
- Confirm the final number of shares issued and the exact gross proceeds received.
- Review the Company's most recent Form 10-Q for updated cash runway and liquidity status.
- Monitor the filing and effectiveness of the registration statement for the resale of securities.
- Assess the dilution impact of the 14.6 million+ shares issuable upon full exercise of all warrants.